Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma announced signing a definitive agreement to acquire Organon & Company for $14 per share, representing an equity value of $3.99 billion and an enterprise value of $11.75 billion. The deal is expected to close in 6-9 months pending shareholder and regulatory approvals. Sun Pharma will fund the acquisition using $2-2.5 billion of its own cash ($3.1 billion in existing cash reserves) and the balance through committed bank financing. The combined entity will have revenues of approximately $12.4 billion, with innovative medicine revenue growing from 20% to 27% of the combined business. Management projects $350 million in cost synergies over 2-4 years primarily from procurement, supply chain, and shared talent. The company expects the deal to be EPS accretive from day one, though it will move from a net cash position to a net debt of 2.3x EBITDA (Organon carries gross debt of $8.5 billion at 5.5% interest cost). Management drew parallels to the Ranbaxy acquisition, citing similar relative size and the opportunity to restore growth in a stagnant business using Sun's execution capabilities.
The acquisition transforms Sun Pharma into a top-25 global pharma company with expanded geographic footprint (150+ markets), a 24,000-person commercial team, and entry into the biosimilars segment. However, the significant debt load (net debt ~2.3x EBITDA) and management bandwidth required for integration may weigh on the stock in the near term, especially given past lessons from the Ranbaxy integration. Long-term, the China market entry ($800 million Organon revenue) and cross-selling opportunities offer significant upside.